Surrey Heartlands

Joint Formulary & PAD

Colesevelam hydrochloride - Lipid modification

You are here : Home > Formulary Search > Colesevelam hydrochloride - Lipid modification

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important
Hypercholesterolaemia. Primary care prescribing on specialist team recommendation.

Documentation

Guidelines (National)
NICE Clinical guideline [CG71] : Familial hypercholesterolaemia: identification and management

PAD Profile

ChemicalSubstance :
Colesevelam hydrochloride
Indication :
Lipid modification
Group Name :
Keywords :
high cholesterol, raised cholesterol, lipid lowering, hyperlipidaemia, FH, familial hypercholesterolaemia, lipid modifying drugs
Brand Names Include :
Cholestagel
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Lipid modification
Supporting Documents :
1

Other Indications

Below are listed other indications that Colesevelam hydrochloride is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Lipid modification.

Committee Recommendations (1)

01 Mar 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN recommends, as per NICE CG71 (updated July 2016), that patients with Familial Hyperchosterolaemia (FH) with intolerance or contraindications to statins or ezetimibe, should be offered a referral to a specialist with expertise in FH for consideration for treatment with either a bile acid sequestrant (resin), nicotinic acid or a fibrate to reduce their LDL-C concentration. For those patients, bile acid sequestrants should be considered BLUE (without an information sheet) on the traffic light system Specialists to initiate treatment or make a recommendation for the primary care prescriber to initiate treatment.

See below for policy statement and further information